Self-assessment of immediate post-vaccination pain after two different MMR vaccines administered as a second dose in 4- to 6-year-old children

Vaccine

Volumn 23, Issue 2, 2004, Pages 127-131

  Wood, C ^a   Baeyer, C L Von ^b   Bourrillon, A ^a   Dejos Conant, V ^c   Clyti, N ^c   Abitbol, V ^c  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c GLAXOSMITHKLINE   (France)

Author keywords

FPS R.; MMR; Pain

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE; RORVAX;

AGE DISTRIBUTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; INCIDENCE; MALE; MEASLES; MUMPS; NORMAL HUMAN; PAIN; PAIN ASSESSMENT; PARENT; PEDIATRICIAN; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SELF EVALUATION; SELF REPORT; STATISTICAL SIGNIFICANCE; VACCINATION REACTION; VALIDATION PROCESS;

CHILD; CHILD PSYCHOLOGY; CHILD, PRESCHOOL; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MEASLES-MUMPS-RUBELLA VACCINE; MULTICENTER STUDIES; PAIN; PAIN MEASUREMENT; SAFETY; VACCINATION;

EID: 8644260188     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.08.029     Document Type: Article

References (12)

1. H. De Melker The seroepidemiology of measles in Western Europe Epidemiol. Infect. 126 2 2001 249 259
2. D. Lévy-Bruhl, J. Maccario, and S. Richarson Modélisation de la rougeole en France et conséquences pour l'âge de l'administration de la seconde vaccination Rougeole-Oreillons-Rubéole BEH 29 1997 133 135
3. D. Antona, and N. et Guérin Couverture vaccinale Rougeole-Rubéole-Oreillons en France en 1998 - Premire et deuxime doses BEH 19 1999 74 75
4. V. Usonis, V. Bakasenas, and A. Kaufhold Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children Pediatr. Infect. Dis. J. 18 1 1999 42 48
5. K. Chitour A new MMR vaccine Inpharma Weekly Suppl. 1 1999 7 8
6. Arguedas A, Riccheimer R, Rocha C, Cervantes Y, Steens J-M. A randomized, comparative study of a new measles mumps rubella (MMR) vaccine with a widely used MMR vaccine administered as a second dose at 4-6 years of age. In: Proceedings of the 18th Annual Meeting of the European Society for Paediatric Infectious Disease; 2000 (abstract 37).
7. B. Goodenough, L. Addicoat, G.D. Champion, M. McInerney, B. Young, K. Juniper, and J.B. Ziegler Pain in 4- to 6-year-old children receiving intramuscular injections: a comparison of the Faces Pain Scale with other self-report and behavioral measures Clin. J. Pain. 13 1997 60 73
8. C.L. Hicks, C.L. von Baeyer, P.A. Spafford, I. van Korlaar, and B. Goodenough The Faces Pain Scale Revised: toward a common metric in pediatric pain measurement Pain 93 2001 173 183
9. ANAES. Evaluation et stratégies de prise en charge de la douleur aiguë en ambulatoire ches l'enfant de un mois 15 ans. Texte des recommendations de l'Agence nationale d'accréditation et d'évaluation en santé. Arch Pédiatr, 2001;8:420-32.
10. ® administré en premire dose au cours de la 2me année de vie, en seconde dose l'âge de 3-6 ans ou de 11-13 ans, ou en dose de "rattrapage" l'âge de 11-13 ans. Data on file, GSK Biologicals 2001.
11. Ipp M, Cohen E, Goldbach M, Macarthur C. Pain response to two licenced measles-mumps-rubella (MMR) vaccines in pre-school children: a randomized comparative study. In: Proceedings of the Annual Meeting of the Pediatric Academic Societies, 4-7 May 2002. Baltimore Convention Center (abstract 900).
12. Ipp M, Cohen E, Goldbach M, Macarthur C. MMR vaccination at 12 months of age. In: Proceedings of the 5th Canadian National Immunization Conference; 2002 (abstract P30).